Showing posts from March, 2015

Silicon Valley parallels to Wolf of Wall Street

I really hope Ellen Pao's gender discrimination lawsuit against venture capital firm Kleiner Perkins Caulfield Byers, is the straw that breaks the camel's back. Pao's lawsuit against her former employer cited three causes of action: (1) employment discrimination based on gender, (2) workplace retailiation, and (3) failure to take reasonable steps to prevent gender discrimination.

There's a great liveblog of the arguments at Re/Code by Liz Gomez and Nellie Bowles, and Katie Benner's introduction to the case on Bloomberg (as well as her previous work in Fortune) are thorough and engaging. (Hint: Pao and husband, Buddy Fletcher, are very flawed protagonists.)

Reaction to William Deresiewicz's Excellent Sheep

I just finished reading William Deresiewicz’s Excellent Sheep, a best-seller whose lament for America's culture of achievement rings familiar; this same message is echoed in much of Venture for America’s marketing, including our founder and CEO Andrew Yang's Smart People Should Build Things.

Update: Pharmaceutical pricing

An article in this month's Chemical & Engineering News (unfortunately, the link is only available to subscribers) suggested that innovative pricing models might lead the way towards cheaper drug pricing in the US. Pharmaceutical benefits managers are now amortizing the costs of treating select illnesses, rather than pay per pill. This new pricing plan would cut costs over time, particularly for long-term illnesses, such as Hepatitis C, where costs may exceed $1,000 per pill.

This post is an update to: The high price of prescription drugs